Kangmei Pharmaceutical Co.Ltd(600518) ( Kangmei Pharmaceutical Co.Ltd(600518) , 600518) release performance forecast.
On January 27, Kangmei Pharmaceutical Co.Ltd(600518) announced that it is expected to realize the net profit attributable to shareholders of Listed Companies in 2021. Compared with the same period of last year, it will turn losses into profits, and realize the net profit attributable to shareholders of listed companies from 5.625 billion yuan to 8.438 billion yuan. The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was -8.64 billion yuan to -5.76 billion yuan.
The announcement said that the performance pre profit was mainly due to the completion of the implementation of the Kangmei Pharmaceutical Co.Ltd(600518) reorganization plan (hereinafter referred to as the “reorganization plan”), realizing a net reorganization income of about 17.5 billion yuan; At the same time, based on the principle of prudence, the company made provision for impairment of various assets of about 4.8 billion yuan; According to the results of relevant judgments, the amount of civil litigation claims of investors was increased by about 1.459 billion yuan.
On January 10 this year, the Guangdong Provincial Higher People’s court made a final ruling on the case of Ma Xingtian, the former chairman of Kangmei pharmaceutical, who manipulated the securities market, rejected the appeal and upheld the original judgment.
On November 17 last year, the intermediate people’s Court of Foshan City, Guangdong Province sentenced Ma Xingtian to fixed-term imprisonment of 12 years and a fine of 1.2 million yuan for the crime of manipulating the securities market, illegal disclosure, non disclosure of important information and unit bribery; Xu Dongjin, former vice chairman of Kangmei pharmaceutical, and other 11 defendants were sentenced to fixed-term imprisonment of six years to six months and fined.
On December 30 last year, Kangmei Pharmaceutical Co.Ltd(600518) announced that the company had recently received the civil ruling (2021) Yue 52 Po No. 1-4 from the court, which ruled that the reorganization plan had been implemented.
As of the closing on January 27, Kangmei Pharmaceutical Co.Ltd(600518) (600518) closed at 3.04 yuan, up 0.66%.
